Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
The recent FDA-approval for amyloid lowering therapies reflects an unwavering commitment from the Alzheimer's disease (AD) research community to identify treatments for this leading cause of dementia. The clinical benefits achieved by reducing amyloid, though modest, provide evidence that disease modification is possible. Expanding the same tenacity to interventions targeting upstream drivers of AD pathogenesis could significantly impact the disease course. Advanced age is the greatest risk factor for developing AD. Interventions targeting biological aging offer the possibility of disrupting a foundational cause of AD. Senescent cells accumulate with age and contribute to inflammation and age-related diseases like AD. Senolytic drugs that clear senescent cells improve healthy aging, halt AD disease progression in animal models and are undergoing clinical testing. This review explores the biology of aging, the role of senescent cells in AD pathology, and various senotherapeutic approaches such as senolytics, dampening the SASP (senescence associated secretory phenotype), senescence pathway inhibition, vaccines, and prodrugs. We highlight ongoing clinical trials evaluating the safety and efficacy of the most advanced senolytic approach, dasatinib and quercetin (D+Q), including an ongoing Phase II senolytic trial supported by the Alzheimer's Drug Discovery Foundation (ADDF). Challenges in the field of senotherapy for AD, including target engagement and biomarker development, are addressed. Ultimately, this research pursuit may lead to an effective treatment for AD and provide the field with another disease-modifying therapy to be used, alone or in combination, with other emerging treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Hallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“One major hurdle in drug development is an incomplete understanding of the underlying mechanisms that drive A β plaques and tau-containing neurofibrillary tangles (NFTs) in the brain which may begin decades prior to cognitive decline (9–11).”
BackgroundRapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 1×
“…to interact either with NF-κ B and C/EBP β transcriptional activities at different levels have been developed (summarized in: 81). mTOR inhibition— Rapamycin is a well-studied FDA approved immunosuppressive drug that has been shown to extend lifespan in yeast, worms, flies, and mice (83, 84).”
BackgroundClearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670 · cited 1×
“Proof of principle experiments utilizing genetically engineered progeroid mouse models conclusively demonstrated that senescent cells contribute to poor aging (43).”
BackgroundNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 1×
“A later study using the same genetic approach to clear senescent cells, but this time in naturally aging mice, provided further evidence that removing senescent cells improves healthy aging (44).”
BackgroundThe molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 9×
“The approach revealed that the anti-apoptotic survival of senescent cells relied on six senescent-cell anti-apoptotic pathways (SCAPs) (45, 46).”
BackgroundResultInfluentialAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“For example, the amyloid hypothesis (16, 17) aligns with the decline in proteostasis (a primary hallmark); the cholinergic hypothesis (18) reflects deficits in intercellular communication; the mitochondrial cascade hypothesis (19) falls under an antagonistic hallmark; while the inflammatory…”
BackgroundSenolytics improve physical function and increase lifespan in old age
Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0092-9 · Cited by 2,287 · cited 1×
“In tau transgenic mice we saw improvements in brain structure and function by reducing senescent cell burden by 30% with an intermittent treatment strategy (35), which is consistent with preclinical studies on other models of aging and/or disease (37, 45, 46, 101–103 , 108– 112).”
Result
Cited by
Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions
Saliev, T., & Singh, P. B. (2025) · Biomolecules · doi:10.3390/biom15060860 · Cited by 160
Therapeutic targeting of senescent cells in the CNS
Riessland, M., Ximerakis, M., Jarjour, A. A., Zhang, B., & Orr, M. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01033-z · Cited by 77
Self-citationTargeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Alum, E., Izah, S., Uti, D., Ugwu, O., Betiang, P., Basajja, M., & Ejemot-Nwadiaro, R. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s543211 · Cited by 63
Garbarino, V. R., Palavicini, J. P., Melendez, J., Barthelemy, N. R., He, Y., Kautz, T. F., Lopez-Cruzan, M., Mathews, J. J., Xu, P., Zhang, B., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00591 · Cited by 26
“An on-going phase 2 trial will measure SASP related factors at multiple time points after the fi nal D þ Q dose, which may help differentiate acute versus chronic effects of treat-ment and clarify the discrepant results between pilot trials (Clinical-Trials.gov: NCT04685590) [12].”
InfluentialSelf-citation
Metadata
- Authors
- Riessland, M., & Orr, M. E.
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-11
- Volume
- 10
- Issue
- 4
- Pages
- 633-646
- ISSN
- 2274-5807 (ISSN-L)
- OpenAlex
- W4387893426
- Cited by
- 52
- References
- 82
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics. https://app.cochat.ai/papers/10.14283/jpad.2023.104
- The paper
- Riessland, M., & Orr, M. E. (2023). Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.14283/jpad.2023.104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.